Nov. 4, 2024—Qiagen announced that the FDA has cleared the QIAstat-Dx Meningitis/Encephalitis panel for clinical use. The panel simultaneously analyzes several of the most common viral, bacterial, and fungal pathogens responsible for community-acquired meningitis/encephalitis. The QIAstat-Dx system delivers results in about one hour with real-time PCR. Results include cycle threshold values and amplification curves, which offer immediately viewable information for detected pathogens and provide health care professionals with additional clinical information not available with end-point PCR or other techniques.
The FDA has cleared three other QIAstat-Dx tests this year, the QIAstat-Dx Gastrointestinal Panel 2, QIAstat-Dx Respiratory Panel Plus, and QIAstat-Dx Respiratory Panel Mini.